Clinical Trial Update: Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a tumor antigen peptide vaccine with imiquimod for children with recurrent ependymoma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma

Drugs mentioned

• Imiquimod (imiquimod)
• Tumor antigen peptide vaccine (peptide vaccine)

Snippet

Sponsor: James Felker | Conditions: Ependymoma | Phase 1 | Status: TERMINATED